Summary

Induced Pluripotent Stem Cells Production Market Growth & Trends

The global induced pluripotent stem cells production market size is estimated to reach USD 2.76 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.3% from 2023 to 2030. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.

The rising research activities during COVID-19 pandemic have positively impacted the market. The pandemic fueled research in many fields as the SARS CoV-2 infection resulted in many diseases in the patients. For instance, in April 2021, researchers from USA stated that up to 25% of COVID-19 patients suffered cardiac dysfunction. Through their research article, they demonstrated the pathogenesis via exposure of iPSCs-derived cardiac cells to SARS CoV-2, and similar alterations were confirmed from human autopsy specimens of the patients. Such insights allow the use of induced pluripotent stem cells (iPSCs) as drug or therapy development platforms and their utilization in the management of the long-term effects of COVID-19.

Induced pluripotent stem cells are cells that are derived from adult somatic cells and then further reprogrammed to obtain the pluripotency as that of ESCs. These iPSCs are proving to be an ethically uncomplicated alternative for research that involves ESCs. The derivation of the ESCs is associated with the destruction of an embryo at the blastocyte stage, which has led to a maximum number of ethical debates. However, induced pluripotent stem cells have solved the ethical issue over the destruction of human embryos in research by involving only the genetic reprogramming of somatic cells. This has propelled the market growth and resulted in numerous applications including drug discovery, disease modeling, toxicology testing, and many others. For instance, in August 2021, Fate Therapeutics announced the treatment of the first patient with FT819 during clinical trials. FT819 is an engineered CAR-T cell therapy that is derived from iPSCs. Also, the rising focus of the research community on exploring applications of induced pluripotent stem cells in regenerative medicine due to their unique characteristics such as differential potential, self-renewable, immunomodulatory properties, and others; is set to drive the market expansion.

Induced Pluripotent Stem Cells Production Market Report Highlights

• By process, the manual iPSC production process segment dominated the market and accounted for the largest revenue share of 77.2% in 2022.

• By workflow, the cell culture segment dominated the market with the largest revenue share of 37.3% in 2022. Cell culture workflow is inclusive of revenues generated from iPSC harvest products, expansion products, and differentiation products; thus contributing to the market relevance of this segment.

• By product, the consumables and kits segment dominated the market and accounted for the largest revenue share of 40.3% in 2022. The never-ceasing research and development activities in the iPSCs space are driving the demand for various consumables & kits.

• By application, drug development & discovery segment dominated the market with the largest revenue share of 43.3% in 2022.

• By end-user, the biotechnology and pharmaceutical companies segment dominated the market with the largest revenue share of 59.3% in 2022. The availability and adoption of various kits, consumables, and instruments along with iPSCs products are driving the revenue generation in this segment.

• North America dominated the market and accounted for the largest revenue share of 40.8% in 2022. The growing incidence of chronic diseases in this region, developed healthcare infrastructure, funds from private & government initiatives, and strategic business models are driving the revenue generation in the marketspace.

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Process
1.1.2. Workflow
1.1.3. Product
1.1.4. Application
1.1.5. End use
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Process outlook
2.2.2. Workflow outlook
2.2.3. Product outlook
2.2.4. Application outlook
2.2.5. End use outlook
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Induced Pluripotent Stem Cells Production Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Induced Pluripotent Stem Cells Production Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Induced Pluripotent Stem Cells Production: Process Estimates & Trend Analysis
4.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
4.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Manual iPSC Production Process
4.3.1. Manual iPSC production process market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Automated iPSC Production Process
4.4.1. Automated iPSC production process market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Induced Pluripotent Stem Cells Production: Workflow Estimates & Trend Analysis
5.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
5.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Reprogramming
5.3.1. Reprogramming market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Cell Culture
5.4.1. Cell culture market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Cell Characterization / Analysis
5.5.1. Cell characterization / analysis market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Engineering
5.6.1. Engineering market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Induced Pluripotent Stem Cells Production: Product Estimates & Trend Analysis
6.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
6.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Instruments/ Devices
6.3.1. Instruments/ devices market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Automated Platforms
6.4.1. Automated platforms market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Consumables & Kits
6.5.1. Consumables & kits market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.2. Media
6.5.2.1. Media market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.3. Kits
6.5.3.1. Kits market estimates and forecasts, 2018 to 2030 (USD Million)
6.5.4. Others
6.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Services
6.6.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Induced Pluripotent Stem Cells Production: Application Estimates & Trend Analysis
7.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
7.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
7.3. Drug Development & Discovery
7.3.1. Drug development & discovery market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Regenerative Medicine
7.4.1. Regenerative medicine market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Toxicology Studies
7.5.1. Toxicology studies market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Others
7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Induced Pluripotent Stem Cells Production: End Use Estimates & Trend Analysis
8.1. Induced Pluripotent Stem Cells Production Market: Key Takeaways
8.2. Induced Pluripotent Stem Cells Production Market: Movement & Market Share Analysis, 2022 & 2030
8.3. Research & Academic Institutes
8.3.1. Research & academic institutes market estimates and forecasts, 2018 to 2030 (USD Million)
8.4. Biotechnology & Pharmaceutical Companies
8.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
8.5. Hospitals & Clinics
8.5.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 9. Induced Pluripotent Stem Cells Production: Regional Estimates & Trend Analysis
9.1. Regional Outlook
9.2. Induced Pluripotent Stem Cells Production Market by Region: Key Marketplace Takeaway
9.3. North America
9.3.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.3.2. U.S.
9.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.3.3. Canada
9.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4. Europe
9.4.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.2. UK
9.4.2.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.3. Germany
9.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.4. France
9.4.4.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.5. Italy
9.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.6. Spain
9.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.7. Sweden
9.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.8. Norway
9.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.4.9. Denmark
9.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5. Asia Pacific
9.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.2. Japan
9.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.3. China
9.5.3.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.4. India
9.5.4.1. India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.5. Australia
9.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.6. Thailand
9.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.5.7. South Korea
9.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.6. Latin America
9.6.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.6.2. Brazil
9.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.6.3. Mexico
9.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.6.4. Argentina
9.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7. MEA
9.7.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7.2. Saudi Arabia
9.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7.3. South Africa
9.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7.4. UAE
9.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
9.7.5. Kuwait
9.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Market Participant Categorization
10.2.1. Lonza
10.2.1.1. Company overview
10.2.1.2. Financial performance
10.2.1.3. Product benchmarking
10.2.1.4. Strategic initiatives
10.2.2. Axol Biosciences Ltd.
10.2.2.1. Company overview
10.2.2.2. Financial performance
10.2.2.3. Product benchmarking
10.2.2.4. Strategic initiatives
10.2.3. Evotec Se
10.2.3.1. Company overview
10.2.3.2. Financial performance
10.2.3.3. Product benchmarking
10.2.3.4. Strategic initiatives
10.2.4. Hitachi Ltd.
10.2.4.1. Company overview
10.2.4.2. Financial performance
10.2.4.3. Product benchmarking
10.2.4.4. Strategic initiatives
10.2.5. Reprocells Inc.
10.2.5.1. Company overview
10.2.5.2. Financial performance
10.2.5.3. Product benchmarking
10.2.5.4. Strategic initiatives
10.2.6. Fate Therapeutics
10.2.6.1. Company overview
10.2.6.2. Financial performance
10.2.6.3. Product benchmarking
10.2.6.4. Strategic initiatives
10.2.7. Thermo Fisher Scientific, Inc.
10.2.7.1. Company overview
10.2.7.2. Financial performance
10.2.7.3. Product benchmarking
10.2.7.4. Strategic initiatives
10.2.8. Merck Kgaa
10.2.8.1. Company overview
10.2.8.2. Financial performance
10.2.8.3. Product benchmarking
10.2.8.4. Strategic initiatives
10.2.9. StemCellsFactory III
10.2.9.1. Company overview
10.2.9.2. Financial performance
10.2.9.3. Product benchmarking
10.2.9.4. Strategic initiatives
10.2.10. Applied StemCells, Inc.
10.2.10.1. Company overview
10.2.10.2. Financial performance
10.2.10.3. Product benchmarking
10.2.10.4. Strategic initiatives